Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-TriCAR-T/SILK in Children with CD19+ Leukemia and Non-Hodgkin Lymphoma
NCT03910842Phase 1Unknown
- Sponsor
- Timmune Biotech
- Start
- Mar 2019
- Primary completion
- Apr 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19-TriCAR-T in B-cell leukemia (BCL) and B-cell non-Hodgkin lymphoma, sponsored by Timmune Biotech. Primary endpoint: Incidence of treatment-related adverse events at 24 months. Status: unknown.
02
Drugs
CD19-TriCAR-T
03
Conditions
B-cell leukemia (BCL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03910842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910842.